title: Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
authors: Mario
authors: M
authors: Mandalà
authors: Cecilia
authors: C
authors: Moro
authors: Roberto
authors: R
authors: Labianca
authors: Gianluigi
authors: G
authors: Ferretti
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D000069347:Erlotinib Hydrochloride; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012107:Research Design; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; D000069347:Erlotinib Hydrochloride